US Markets for Neurostimulation Devices
This article was originally published in Start Up
Executive Summary
The market for neurostimulation products in the US was valued at approximately $1.3 billion in 2009 and it hasn't even scratched the surface of its potential. According to "US Markets for Neurostimulation Products," a report published in March by the Medtech Insight division of Elsevier Business Intelligence, this market is projected to grow at a healthy compound annual rate of almost 16%, reaching more than $2.7 billion five years from now.
You may also be interested in...
Device Investors Look for Gains in Pain
In 2009, investors quietly invested in seven different start-ups develoipng devices for pain. Why the sudden interest? Interventional pain is on the rise as a specialty, large numbers of patients with chronic pain need better therapies, and relative to other emerging device sectors, pain offers large markets but lower clinical, regulatory and market risks.
A Boom in Devices for the Hearing Impaired
Competition is spurring innovation in the hearing aid market and providers are excited at the prospect of adopting new products that can improve on existing treatments. The hottest area at the moment is implantable hearing aid devices. It's not a new concept, but it's one that many believe will command a significant share of the market.
Seizure Desist: Neurostim Companies Pursue Alternative Treatments for Epilepsy
The rise of interest in neurostimulation and neuromodulation approaches is leading venture capitalists and large medical device companies to develop devices to prevent or block seizures. The devices would be used primarily on patients who don't respond to drugs for epilepsy.